CORE--CLINICAL

核心A(临床核心)有三个目标：1.登记和描述ALL 急性肺损伤(ALI)或急性呼吸窘迫 综合症(ARDS)；2.提供接触病人和临床样本的途径 来自选定的ALI/ARDS患者或ALI/ARDS高危患者 3.促进内部协调。 这个SCOR和ALI SCOR之间。这一核心有以下四个具体的 目标： 1.有ALI/ARDS(创伤)风险的重大创伤患者登记 队列)：建立重大创伤患者的预期登记 入住威尔斯亲王医院外科深切治疗部 宾夕法尼亚大学(HUP)和内外科ICU白兰地 医院(BWH)在前5天内有发生ALI/ARDS的风险 在创伤后。这一登记将构成未来队列的基础 项目中重大创伤患者的嵌套式病例对照研究 1和3。 2.有ALI/ARDS风险的脓毒症患者登记(脓毒症队列)： 建立一份住院的脓毒症患者的预期登记表 在接下来的头5天内有发生ALI/ARDS风险的ICU 脓毒症的发病。这一登记将构成未来 项目中脓毒症患者的队列和巢式病例对照研究 1和3。 3.所有ALI和ARDS患者的登记：发展和维持一个 通过识别重症监护病房(ICU)确定预期的ALI/ARDS登记 急性肺损伤(ALI)或急性呼吸窘迫 综合征(ARDS)。该登记表的子集，即ARDS患者 与严重创伤或脓毒症相关的，将用于 项目1和项目3中的ARDS队列研究，并将被纳入为 Dl-α生育酚随机临床试验的受试者 项目三中的抗氧化剂。 4.为患者组织临床数据和样本采集系统 正在研究的人口：提供一个有组织的系统来收集和 将临床数据输入SCOR中央数据库，并收集和 为未来队列分配血液和尿液样本 涉及有患病风险的患者的嵌套式病例对照研究 项目1和3中的ALI/ARDS(上文具体目标2和3)以及 对ARDS患者的研究(具体目标3，上文)。

Core A (Clinical Core) has three goals: 1. to enroll and characterize all patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS); 2. to provide access to patients and clinical samples from selected patients with ALI/ARDS or from those at risk for ALI/ARDS for the SCOR research projects; and 3. to facilitate coordination within this SCOR and among ALI SCOR. This Core has the following four specific aims: 1. Registry of Patients with Major Trauma At Risk for ALI/ARDS (Trauma Cohort): To develop a prospective registry of patients with major trauma admitted to Surgical Intensive Care Unit (ICU) at the Hospital of the University of Pennsylvania (HUP) and the Medical-Surgical ICU Brandywine Hospital (BWH) who are at risk for developing ALI/ARDS in the first 5 days after trauma. This registry will form the basis of the prospective cohort and nested case-control studies of patients with major trauma in Projects 1 and 3. 2. Registry of Patients with Sepsis At Risk for ALI/ARDS (Sepsis Cohort): To develop a prospective registry of patients with sepsis admitted to the ICUs who are at risk for developing ALI/ARDS in the first 5 days after onset of sepsis. This registry will form the basis of the prospective cohort and nested case-control studies of patients with sepsis in Projects 1 and 3. 3. Registry of All Patients with ALI and ARDS: To develop and maintain a prospective ALI/ARDS Registry by identifying intensive care unit (ICU) patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Subsets of this registry, i.e., patients with ARDS associated with major trauma or sepsis, will be used for the prospective cohort studies of ARDS in Projects 1 and 3 and will be enrolled as subjects in the randomized clinical trial of dl-alpha tocopherol as an anti-oxidant in Project 3. 4. Organized Clinical Data and Sample Collection System for Patient Populations under Study: To provide an organized system to collect and enter clinical data into the SCOR Central Data Base and to collect and distribute samples of blood and urine for the prospective cohort and nestled case-control studies involving patients who are at risk for ALI/ARDS (Specific Aims 2 and 3, above) in Projects 1 and 3 as well as the studies of patients with ARDS (Specific Aim 3, above).